---
document_datetime: 2025-04-04 14:09:30
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ajovy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ajovy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.5205055
conversion_datetime: 2025-12-28 01:01:45.136845
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## AJOVY

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0052              | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product | 27/03/2025                          |                                             | SmPC, Annex II and PL            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0051             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                         | 23/10/2024   | n/a   |                 |                                                                      |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------|----------------------------------------------------------------------|
| IA/0050             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17/09/2024   |       | Annex II and PL |                                                                      |
| IB/0048             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                         | 19/06/2024   | n/a   |                 |                                                                      |
| IB/0049             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                               | 17/06/2024   | n/a   |                 |                                                                      |
| II/0047             | Submission of the final report from the PASS study TV48125-MH-50039 listed as a category 3 study in the RMP. This is a long-term, prospective, observational study to evaluate the safety, including cardiovascular safety, of fremanezumab in patients with migraine in routine clinical practice. The RMP version 6.0 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 11/04/2024   | n/a   |                 | Submission of the final report from the PASS study TV48125-MH-50039. |
| PSUSA/10758 /202309 | Periodic Safety Update EU Single assessment - fremanezumab                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/04/2024   | n/a   |                 | PRAC Recommendation - maintenance                                    |

<div style=\"page-break-after: always\"></div>

| IB/0046   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21/12/2023   | n/a        |                                                                                                                                                                                                                                                                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0044    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/09/2023   | 06/11/2023 | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of AJOVY in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0041/G | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting | 11/08/2023   | n/a        |                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IB/0043             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                           | 06/07/2023   | n/a   |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IB/0042             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                            | 26/06/2023   | n/a   |                                   |
| II/0039             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 12/05/2023   | n/a   |                                   |
| IB/0040             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                   | 08/05/2023   | n/a   |                                   |
| PSUSA/10758 /202209 | Periodic Safety Update EU Single assessment - fremanezumab                                                                                                                                                                                                                                     | 14/04/2023   | n/a   | PRAC Recommendation - maintenance |
| IB/0038             | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                 | 28/02/2023   | n/a   |                                   |
| IB/0035/G           | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters                                                                                                                                                                                          | 25/01/2023   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|         | AS, starting material/intermediate/reagent - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                |            |            |    | and/or limits of an   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------|
|         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 06/12/2022 | n/a        |    | IA/0037/G             |
| IA/0034 | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                               | 22/08/2022 | n/a        |    |                       |
| IB/0033 | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                           | 12/08/2022 | n/a        |    |                       |
| N/0032  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                  | 02/06/2022 | 27/04/2023 | PL |                       |

<div style=\"page-break-after: always\"></div>

| IB/0031             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                              | 06/05/2022   | 27/04/2023   | SmPC and PL   |                                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029             | Submission of an updated RMP version 3.0 in line with the PI changes which were implemented following the assessment of PSUSA/202103 with regards to severe hypersensitivity reactions. The MAH has also taken the opportunity to update the PASS details according to the latest approved PASS protocols. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH | 07/04/2022   | n/a          |               | Submission of an updated RMP version 3.0 to remove severe hypersensitivity reactions from the list of important potential risks and update PASS protocols. |
| PSUSA/10758 /202109 | Periodic Safety Update EU Single assessment - fremanezumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 07/04/2022   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                          |
| IB/0030             | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/03/2022   | n/a          |               |                                                                                                                                                            |
| IB/0028/G           | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                  | 27/01/2022   | n/a          |               |                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                  |            |            |             |                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10758 /202103 | Periodic Safety Update EU Single assessment - fremanezumab                                                                                                                                                                                                                                                                  | 14/10/2021 | 13/12/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10758/202103. |
| IA/0027/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 07/12/2021 | n/a        |             |                                                                                                                                            |
| IB/0025             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                      | 03/11/2021 | n/a        |             |                                                                                                                                            |
| II/0022             | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                              | 09/09/2021 | n/a        |             |                                                                                                                                            |
| IB/0024             | B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                                 | 20/08/2021 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0023             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                | 05/08/2021   | n/a        |                        |                                                             |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------|
| IB/0021             | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                           | 25/06/2021   | n/a        |                        |                                                             |
| IB/0018/G           | This was an application for a group of variations. B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.b.3.z - Change in the manufacturing process of | 23/06/2021   | 22/09/2021 | SmPC, Labelling and PL | To change the storage conditions and extend the shelf-life. |
| IA/0019             | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                          | 20/05/2021   | n/a        |                        |                                                             |
| PSUSA/10758 /202009 | Periodic Safety Update EU Single assessment - fremanezumab                                                                                                                                                                                                                                                                                                                                                          | 09/04/2021   | n/a        |                        | PRAC Recommendation - maintenance                           |
| IA/0017             | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                          | 05/03/2021   | n/a        |                        |                                                             |

<div style=\"page-break-after: always\"></div>

| IB/0016             | B.II.b.z - Change in manufacture of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 05/03/2021   | n/a        |                     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------------|-----------------------------------|
| IB/0014/G           | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure | 09/02/2021   | n/a        |                     |                                   |
| PSUSA/10758 /202003 | Periodic Safety Update EU Single assessment - fremanezumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 01/10/2020   | n/a        |                     | PRAC Recommendation - maintenance |
| IB/0013             | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 24/09/2020   | n/a        |                     |                                   |
| II/0011             | B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/09/2020   | n/a        |                     |                                   |
| II/0008/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 03/09/2020   | 22/09/2021 | SmPC, Labelling and |                                   |

<div style=\"page-break-after: always\"></div>

|                     | A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                        |            |            | PL          |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0010             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                           | 07/08/2020 | n/a        |             |                                                                                                                                            |
| IA/0012/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 29/07/2020 | n/a        |             |                                                                                                                                            |
| PSUSA/10758 /201909 | Periodic Safety Update EU Single assessment - fremanezumab                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 30/04/2020 | 26/06/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10758/201909. |
| IA/0007             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                                                                                     | 17/03/2020 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                                                                                                                                                                                                                                                                                                                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 08/01/2020 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                |
| II/0003   | Update of section 4.8 of the SmPC in order to update the safety information based on final results from study TV48125-CNS-30051 listed as a category 3 study in the RMP; A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 28/11/2019 | 26/06/2020 | SmPC and Labelling     | Section 4.8 of the SmPC has been updated to reflect immunogenicity information from study TV48125-CNS- 30051; A Multicenter, Randomized, Double-Blind, Parallel- Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine. |
| IAIN/0004 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                             | 26/11/2019 | 26/06/2020 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                |
| II/0002   | B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                                                                                                                                                                                                                                 | 24/10/2019 | 26/06/2020 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IAIN/0001/G   | This was an application for a group of variations.                                                                                                                                                    | 10/05/2019   | n/a   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
|               | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site |              |       |